Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation

Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML32 AML patients dosed across 40 mg, 80 mg, 120 mg and 160 mg TUS with TUS+VEN+AZA tripletComposite complete response (CRc) rate in evaluable patients across all dosing groups was 86.2%MRD-negativity in patients who achieved a CR/CRh response was 86.4% AML patients with diverse genetics, including TP53-mutated, complex karyotypes, and unmutated FLT3, safe